Global Extracorporeal CO2 Removal Devices market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Artificial gas exchange takes a different route with extracorporeal carbon dioxide removal (ECCO2R). When a person has increased blood levels of carbon dioxide as a result of respiratory failure, extracorporeal carbon dioxide removal is used to reduce those levels.

The market growth is driven by increasing prevalence of COPD and other diseases and increasing numbers of product launches and approvals. For instance, according to a research study released in February 2021 and titled "Burden of COPD among population above 30 years in India: methodology for a systematic review and suggested meta-analysis," the estimated overall prevalence of COPD in low- and middle-income countries was 9.2%, and meta-analysis indicated that the prevalence of COPD among persons aged 30 years and over was 10.6% in low- and middle-income countries. Alung Technologies also received De Novo Clearance for the hemolung respiratory system in November 2021. The FDA has authorized this system as the first ECCO2R product. X-COR Therapeutics completed a fundraising round of around 2.6 million in November 2020. This business plans to use these funds to continue developing its products, which include ECCO2R devices. Moreover, increasing cases of respiratory emergencies and chronic obstructive pulmonary disease and rising preference for safe and rapid minimally invasive ventilation devices propel the market opportunities in the upcoming years. However, risks of complications during extracorporeal co2 removal therapy impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Extracorporeal CO2 Removal Devices Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market revenue share owing to improved healthcare infrastructure and high adoption of extracorporeal CO2 removal devices. However, Asia Pacific is expected to be the fastest growing region due to rising awareness regarding acute respiratory failure and increasing government healthcare expenditure in developing countries.

Major market players included in this report are:

Medtronic

Getinge AB

Xenios AG

Alung Technologies

ESTOR S.P.A

Medica Spa

Aferectica Srl

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

Extracorporeal CO2 Devices

Disposables

Others

By Application:

Chronic Obstructive Pulmonary Disease (COPD)

Acute Respiratory Distress Syndrome (ARDS)

Bridge to Lung Transplant

Others

By End User:

Hospitals and Clinics

Ambulatory Surgical Centers

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Extracorporeal CO2 Removal Devices market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors